Home Alzheimer’s Disease Phase 3 Study Explores Pamrevlumab for Unresectable LAPC

Phase 3 Study Explores Pamrevlumab for Unresectable LAPC

Pamrevlumab is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel (Abraxane) in the phase 3 LAPIS trial as a potential method for downgrading unresectable locally advanced pancreatic cancer (LAPC).

The phase 3 trial (NCT03941093),1 which is currently enrolling, will randomize 256 patients to receive pamrevlumab, a first-in-class inhibitor of connective tissue growth factor (CTGF) activity, or placebo with the chemotherapy doublet prior to surgery. The dual primary end points are improvement in overall survival (OS) and the portion of patients achieving R0 or R1 resection.

“Patients with unresectable LAPC face a dire prognosis. The use of pamrevlumab, a novel antifibrotic used as neoadjuvant therapy, may change tumor status from unresectable to resectable, thus potentially improving the prognosis of the patient,” Pascal Hammel, MD, PhD, a…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments